DDInter1702 DDInter1658
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Sorafenib {u} (Compound) treats {v} (Disease) liver cancer
Sorafenib {u} (Compound) binds {v} (Gene) BRAF
Sorafenib {u} (Compound) upregulates {v} (Gene) TSC22D3
Sorafenib {u} (Compound) downregulates {v} (Gene) MCM3
Sorafenib {u} (Compound) causes {v} (Side Effect) Hepatobiliary disease
Sorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trimipramine
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tacrine
Sorafenib {u} may lead to a major life threatening interaction when taken with {v} Ibutilide
Sorafenib (Compound) resembles Vismodegib (Compound)
Sorafenib (Compound) treats liver cancer (Disease)
Sorafenib (Compound) binds BRAF (Gene)
Sorafenib (Compound) upregulates TSC22D3 (Gene)
Sorafenib (Compound) downregulates MCM3 (Gene)
Sorafenib (Compound) causes Hepatobiliary disease (Side Effect)
Sorafenib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Tacrine
Sorafenib may lead to a major life threatening interaction when taken with Ibutilide